Literature DB >> 11897868

Gene repair and transposon-mediated gene therapy.

Paul D Richardson1, Lance B Augustin, Betsy T Kren, Clifford J Steer.   

Abstract

The main strategy of gene therapy has traditionally been focused on gene augmentation. This approach typically involves the introduction of an expression system designed to express a specific protein in the transfected cell. Both the basic and clinical sciences have generated enough information to suggest that gene therapy would eventually alter the fundamental practice of modern medicine. However, despite progress in the field, widespread clinical applications and success have not been achieved. The myriad deficiencies associated with gene augmentation have resulted in the development of alternative approaches to treat inherited and acquired genetic disorders. One, derived primarily from the pioneering work of homologous recombination, is gene repair. Simply stated, the process involves targeting the mutation in situ for gene correction and a return to normal gene function. Site-specific genetic repair has many advantages over augmentation although it too is associated with significant limitations. This review outlines the advantages and disadvantages of gene correction. In particular, we discuss technologies based on chimeric RNA/DNA oligonucleotides, single-stranded and triplex-forming oligonucleotides, and small fragment homologous replacement. While each of these approaches is different, they all share a number of common characteristics, including the need for efficient delivery of nucleic acids to the nucleus. In addition, we review the potential application of a novel and exciting nonviral gene augmentation strategy--the Sleeping Beauty transposon system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897868     DOI: 10.1634/stemcells.20-2-105

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  8 in total

1.  Transcription affects formation and processing of intermediates in oligonucleotide-mediated gene alteration.

Authors:  Olga Igoucheva; Vitali Alexeev; Melissa Pryce; Kyonggeun Yoon
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

Review 2.  Sequence-specific modification of genomic DNA by small DNA fragments.

Authors:  Dieter C Gruenert; Emanuela Bruscia; Giuseppe Novelli; Alessia Colosimo; Bruno Dallapiccola; Federica Sangiuolo; Kaarin K Goncz
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 3.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

4.  Sleeping beauty transposase has an affinity for heterochromatin conformation.

Authors:  Ryuji Ikeda; Chikara Kokubu; Kosuke Yusa; Vincent W Keng; Kyoji Horie; Junji Takeda
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

Review 5.  Cftr gene targeting in mouse embryonic stem cells mediated by Small Fragment Homologous Replacement (SFHR).

Authors:  Federica Sangiuolo; Maria Lucia Scaldaferri; Antonio Filareto; Paola Spitalieri; Lorenzo Guerra; Maria Favia; Rosa Caroppo; Ruggiero Mango; Emanuela Bruscia; Dieter C Gruenert; Valeria Casavola; Massimo De Felici; Giuseppe Novelli
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  Gene therapy for gastric cancer: a review.

Authors:  Chao Zhang; Zhan-Kui Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 7.  Current status of gene therapy for inherited lung diseases.

Authors:  Ryan A Driskell; John F Engelhardt
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

8.  An important role for RUNX3 in human L1 transcription and retrotransposition.

Authors:  Nuo Yang; Lin Zhang; Yue Zhang; Haig H Kazazian
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.